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ABSTRACT  
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
Methylcobalamin alone or in combination with Lidocaine is clinically more effective than 
Lidocaine alone in relieving Herpes Zoster related neuropathic pain with subcutaneous 
injections.  
 
STUDY DESIGN: This is a systematic review of three peer-reviewed primary studies. All were 
randomized, controlled trials published between the years of 2014 and 2016. 
 
DATA SOURCES: Data sources obtained for this review were published in peer reviewed 
journals and selected from PubMed Database. 
 
OUTCOME MEASURED: The outcomes measured reflected the effectiveness of incorporating 
subcutaneous Methylcobalamin in the treatment regimen for neuropathic pain in Herpes Zoster 
patients. The patients in each study reported their pain at baseline and after treatment using an 
11-point NRS to assess a significant change in pain. 
 
RESULTS: All three studies conducted showed significant improvement in Herpes Zoster 
related neuropathic pain for the participants whose treatment regimen included subcutaneous 
Methylcobalamin injections.  
 
CONCLUSIONS: The evidence presented in this review is conclusive that the use of 
subcutaneous injections of Methylcobalamin in the treatment of Herpes Zoster related 
neuropathic pain is significantly more effective than Lidocaine alone.  
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INTRODUCTION 
Herpes Zoster (HZ), commonly known as Shingles, is a condition caused by the 
reactivation of the latent varicella zoster virus (VZV). The virus initially causes the condition 
known as Chicken Pox and lies dormant in the dorsal root ganglia after recovery. With viral 
reactivation, HZ is characterized by vesicles, pruritis, and neuropathic pain in a unilateral 
dermatomal distribution of the affected nerve.1,2,3 The disease generally lasts between 7-10 days, 
while the skin may take 2-4 weeks to return to normal. The most common complication of HZ is 
postherpetic neuralgia (PHN), pain that persists after the rash has subsided. Although 
reactivation is usually benign in children, the pain can be debilitating when HZ presents in 
adults.4 Most patients who experience PHN will have resolution within a few weeks or months. 
However, some people will have pain that persists for years with significant interference with 
their daily life.5 
In order to prevent HZ and the associated PHN complications, the VZ vaccine was 
released for use in the United States in 1995. However, prior to the vaccine availability, almost 
all persons were susceptible to infection of VZV. According to the CDC, thirty percent of the 
current US population will have a reactivation of VZV in their lifetime, leading to significant 
morbidity annually. Incidence rates have shown to increase with age, the highest being in the 
sixth decade and beyond. Though uncommon to have more than one episode, recurring 
reactivations of VZV have been correlated with immunocompromised states, such as individuals 
with AIDs or certain cancers like leukemia.4,5,6  
It is estimated that the United States has one million HZ cases annually. Though a 
majority of these patients can be followed and treated through routine outpatient visits, according 
to the Center of Disease Control and Prevention (CDC), one to four percent of these HZ patients 
Todd, Methylcobalamin Relieving Herpes Zoster Pain 2 
are hospitalized due to complications. Approximately thirty percent of those hospitalized are 
immunocompromised. According to a recent study reported by the CDC, HZ is the underlying 
cause of 96 deaths on average each year.5 In 2004, the United States’ economic burden of HZ 
related healthcare was estimated to be $1.9 billion annually.8 With routine varicella 
immunizations, administration of prophylaxis, and action in removing susceptible personnel 
from possible exposures, national costs involved with postherpetic complications have and will 
continue to be cut down.7 
Although specific populations such as the elderly and immunocompromised are known to 
be at a higher risk for developing HZ, the exact cause of the reactivation of VZV is unknown.5 
Therefore, it is pertinent to find the most effective treatment for HZ and its complications. To 
shorten the length and lessen the severity of the illness, antiviral therapy including acyclovir, 
valacyclovir, and famciclovir are available. Therapy should be administered as soon as possible 
after the rash has appeared. In order to prevent secondary infection, antibiotics can be given. 
Symptomatic relief can be managed with analgesics, wet compresses, or calamine lotion. 
Neuropathic pain treatment currently includes local lidocaine, anticonvulsants, TCAs, and 
cryotherapy.6 
As the risk of HZ increases with age, the risk of developing neuropathic pain increases as 
well, experienced by 10-30% of these patients.5 Although the symptoms usually resolve within 
weeks to months, the pain can last up to years in select patients. Due to the severe interference 
with daily life, it should be evaluated if there are more effective treatments to prevent the painful 
complications of HZ. Clinical use of Methylcobalamin (MeB12) therapy has shown to improve 
symptoms of peripheral neuropathy and autonomic dysfunction.1 It is proposed that including 
Todd, Methylcobalamin Relieving Herpes Zoster Pain 3 
local injections of Methylcobalamin into the treatment regimen of PHN could improve the HZ 
patients’ neurological response. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not 
Methylcobalamin alone or in combination with Lidocaine is clinically more effective than 
Lidocaine alone in relieving HZ related neuropathic pain with subcutaneous injections. 
METHODS 
The studies utilized in this systematic review included three randomized controlled 
studies. The populations were comprised of patients with HZ related neuropathic pain, including 
acute herpetic neuralgia (AHN) and acute ophthalmic herpetic neuralgia (AOHN). The studies 
evaluated the use of subcutaneous (SC) injection of MeB12 in the treatment regimen to improve 
neuropathic pain of the populations. The intervention used in the first study was SC injection 
MeB12 alone1 while the other two studies’ intervention was SC MeB12 combined with SC 
Lidocaine. 2,3 These populations were compared to controlled groups given SC injection of 
Lidocaine alone1 and SC injection of Lidocaine plus IM injection of MeB12. 2,3 The 
demographics and characteristics of the studies are shown in Table 1.  
The keywords “herpes zoster” or “shingles”, “lidocaine”, and “vitamin” were searched to 
locate sources from PubMed Database. The articles were chosen based off of relevance to the 
clinical question and included outcomes that were patient oriented (POEMS). Inclusion criteria 
required studies that were RCTs or other primary research studies and studies that were 
published after 2007. Exclusion criteria included studies using populations with neuropathic pain 
not related to HZ or medication interventions administered by a route other than SC injections. 
All articles were published in English, in peer-reviewed journals, between the years 2014-2016. 
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The statistics reported included Relative Benefit Increase (RBI), Absolute Benefit Increase 
(ABI), Number Needed to Treat (NNT), and 95% Confidence Interval (CI).  
Table 1: Demographics & Characteristics of Included Studies  
Study Type # Pts Age 
(yrs) 
Inclusion Criteria Exclusion Criteria  W/
D 
Interventions 
Xu1, 
2014 
Single 
center, 
RCT 
40 >25  Herpes Zoster dx 
lasting 20-180 
days.  
Experienced 
cutaneous or/and 
subcutaneous itch 
and/or pain in the 
skin. 
U/L itch for < 20 days or 
outside vesicular region. 
Any significant medical 
condition. 
Hypersensitivity to 
thiamine or cobalamin. 
Use of supplement with 
vitamin B. 
Cognitive impairment. 
Topical analgesics or 
nerve blocker use < 10 
days before the baseline. 
5 MeB12 1000 g 
VS. 1.0% 
Lidocaine 
30mg/3.0mL  
- SC daily in 
morning, 6 
days/week for 4 
weeks 
Xu2, 
2016 
Single 
center, 
observer-
blind, 
RCT 
49  >50 AOHN 4-7 days 
after onset of 
vesicles with pain, 
>5 lesions, and 
swelling. Worse 
pain score ≥ 6 in 
past 24 hrs. U/L 
rash on forehead, 
vertex, eyebrow, 
side of nose, or 
regions adjacent. 
U/L pain in vesicular 
region > 7 days after 
rash onset. 
Pain outside the V1 
regions. 
Any significant medical 
condition. 
Cognitive impairment. 
 
1 SC combo of 
MeB12 1000 g 
and 20 mg 
lidocaine (2.0 
mL) VS. IM 
MeB12 plus SC 
lidocaine 
- daily in 
morning, 6 
days/week for 2 
weeks 
Xu3, 
2016 
Single 
center, 
observer-
blind, 
RCT 
89 >50 AHN 4-7 days after 
onset of vesicles 
with pain and > 25 
lesions. Worst pain 
score > 6 in past 24 
hrs. 
U/L rash within 
T5-10 dermatome. 
 
U/L pain in vesicular 
region > 7 days after 
rash onset. 
Pain outside the target 
regions. 
Steroid, analgesics, or 
capsaicin use within 4 
weeks of study entry. 
Any significant medical 
condition. 
Cognitive impairment. 
3 SC combo of 
MeB12 1000 g 
and 20 mg 
lidocaine (2.0 
mL) VS. IM 
MeB12 plus SC 
lidocaine 
- daily in 
morning, 6 
days/week for 2 
weeks 
OUTCOMES MESURED 
Outcomes measured were those of patient-oriented evidence that matters (POEMS). Each 
study used an 11-point numeric rating scale (NRS) (0 = pain, 10 = most painful sensation 
imaginable) to measure the level of neuropathic pain per the patient. The NRS was used at 
baseline and at the end of treatment to measure the extent of pain relief with intervention. Xu1 
baseline was the worst pain over the past 24 hours on the day previous to treatment. Xu2 and Xu3 
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baseline was the worst pain since rash onset. Xu1 endpoint was the worst pain over the past 24 
hours on day 28 of treatment. Xu2 and Xu3 endpoint was the worst pain during the past 24 hours 
on day 14 of treatment.  
RESULTS 
 This review analyzed three randomized controlled studies to assess if the use of SC 
MeB12 would improve relief of HZ related neuropathic pain as compared to SC Lidocaine alone. 
Each study compared a treatment regimen that included SC MeB12 to a controlled treatment 
regimen with only SC Lidocaine. All three studies used dichotomous data.  
 In the study conducted by Xu et al,1 92 participants were assessed for eligibility. 
Inclusion criteria were as follows: a confirmed diagnosis of HZ lasting > 20 days, age > 25 years, 
having pain/itch in the area associated with the HZ rash, and a worst itch NRS score of > 4 in the 
past 24 hours.1 This study was looking at relief of itch symptoms as well as pain. Postherpetic 
itch is not effected by increased age like PHN is, therefore, this study included younger 
participants than other studies observing only PHN. Exclusion criteria were as follows: HZ rash 
lasting < 20 days, neuropathic itch outside the target regions, any clinically significant medical 
condition or severe general disease, cognitive impairment, hypersensitivity to cobalamin, use of 
vitamin B-containing supplements, and use of topical analgesics or nerve blockers in target 
region within 10 days before the baseline visit.1 The final two exclusion criteria were mentioned 
to prevent alteration of reported pain scores. The exclusion of those with HZ < 20 days was to 
prevent the healing or the loss of scabs altering the sensations (itch and pain) measured. 
 After removing participants that did not meet criteria, declined to participate, or other 
reasons, 80 participants were left to be randomized by computer generation and distributed into 4 
groups. For the purpose of this review, only two groups, B12 (n =20) and LD (n =20) were 
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observed. The B12 group received SC injections of MeB12, while the LD group received SC 
1.0% lidocaine injections, into the regions of crusted lesions where the patients experienced 
itching and pain. Frequency of dosing was once daily every morning, 6 times per week for 4 
weeks. The patients were observed for the following hour and discharged without symptoms of 
discomfort. The patients’ NRS pain score was measured from baseline to days 7, 14, and 28 of 
treatment.1 For the purpose of this review, only baseline and day 28 were observed, assessing for 
improvement to a pain score < 3. 
Compliance was measure by the treating physician by recording the number of treatment 
sessions attended by each patient and the number of missed or canceled appointments. Three 
patients were discontinued by the investigator for noncompliance. Two others dropped out due to 
lack of improvement and rapid pain quenched. A total of 5 out of 40 participants (2 of group B12 
and 3 of group LD) dropped out of this study.1  
At baseline, the control and intervention groups had similar mean pain scores. Group B12 
had a mean pain score of 6.65, while group LD had a mean pain score of 6.60. After a treatment 
period of 28 days, 65% of group B12 reported an improved pain score < 3. In contrast, 0% of 
group LD reported a pain score < 3.1 By calculating the NNT to be 2 patients, these results are 
significant. It can be concluded that local MeB12 injection provided a significant reduction in 
HZ neuropathic pain compared to local 1% lidocaine injection. 
Table 2: Pain NRS score at baseline and endpoint of intervention and control group, Xu1 
Xu1 Mean pain NRS at 
Baseline 
% of Pts with pain NRS < 3 at 
28-Day Endpoint 
RBI ABI NNT 
Intervention: 
SC B12 
6.65 (SD 0.88) 0.65 1.00 6.5 2 patients 
(CI n/a) 
Control:  
SC Lido 
6.60 (SD 1.35) 0.0 
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In the study conducted by Xu et al,2 106 participants were assessed for eligibility. 
Inclusion criteria were as follows: AOHN < 7 days after rash onset, >5 lesions on rash, aged >50 
years, severe pain in the region associated with the HZ rash, a worse pain score > 6 in the 
previous 24 hours, and willingness to comply with the allocated treatment and follow-up 
measurements. This study included participants at an older age than Xu1 because HZ neuropathic 
pain increases significantly with age. Exclusion criteria were as following: pain > 7 days after 
rash onset, neuropathic or significant pain outside the V1 regions, any clinically significant 
medical condition or laboratory abnormality, and cognitive impairment.2  
 After meeting criteria, 98 participants enrolled in the study and were randomized by 
computer generation and distributed into control and intervention groups. Those were separated 
out into 4 total groups based on rash onset, a control and intervention group with onset < 3 days 
and a control and intervention group with onset between 4-7 days. For the purpose of this review, 
only the latter two groups were observed, B0 (n =25) and B1 (n =24). The B0 control group 
received IM MeB12 and SC lidocaine injections, while the B1 intervention group received a 
combination SC injection of MeB12 and lidocaine, into the subcutaneous regions of the affected 
V1 innervations where the patients experienced pain. Frequency of dosing was once daily every 
morning, 6 times per week for 2 weeks. The patients were observed for the following hour and 
discharged without symptoms of discomfort. The patients’ NRS pain score was measured at 
baseline and each day of treatment.2 For the purpose of this review, only baseline and day 14 
were observed, assessing for improvement to a pain score < 3. 
Due to lack of improvement after 8 days of treatment, only one participant from B0 
control group dropped out of the study. A total of 1 out of 49 participants (from group B0 and B1) 
were lost.2  
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At baseline, the control and intervention groups had the same mean pain scores at 8.0. 
After a treatment period of 14 days, 96% of group B1 reported an improved pain score < 3. In 
contrast, 16% of group B0 reported a pain score < 3.2 By calculating the NNT to be 2 patients 
along with a CI of 1.03-1.58, these results are significant. It should be noted that the 16% with 
group B0 is a similar rate to the known history of the natural decline of pain in HZ. This makes it 
difficult to prove any benefits of using IM MeB12. It can be concluded that the combination SC 
injection with MeB12 provides a significant reduction in HZ neuropathic pain, in contrast to the 
use of IM MeB12 with SC Lidocaine that showed little benefit to the patients. 
Table 3: Pain NRS score at baseline and endpoint of intervention and control group, Xu2 
Xu2 Mean pain NRS at 
Baseline 
% of Pts with pain NRS < 3 
at 14-Day Endpoint 
RBI ABI NNT 
B1 Intervention:  
SC Combo B12 + Lido 
8.0 (SD 1.0) 0.96 5.00 0.8 2 patients  
(CI  
1.03-1.58) B0 Control:  
IM B12 + SC Lido 
8.0 (SD 1.2) 0.16 
In the study conducted by Xu et al,3 204 participants were assessed for eligibility. 
Inclusion criteria were as follows: AHN from the 5th – 10th intercostal nerve < 7 days after rash 
onset; >25 lesions on rash; aged > 50 years; severe pain on the unilateral T5-10 dermatome 
associated with the HZ rash and a worst pain score of > 6 in the past 24 hours; and willingness to 
comply with the allocated treatment and follow-up measurements.3 Exclusion criteria were as 
follows: pain > 7 days after rash onset; neuropathic or significant pain outside the target regions; 
use of steroid, analgesics, or capsaicin within 4 weeks of study entry; any clinically significant 
medical condition or laboratory abnormality; and cognitive impairment.3  
 After meeting criteria, 180 participants enrolled in the study and were randomized by 
computer generation and distributed into control and intervention groups. Those were separated 
out into 4 total groups based on rash onset, a control and intervention group with onset < 3 days 
and a control and intervention group with onset between 4-7 days. For the purpose of this review, 
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only the latter two groups were observed, ES-Ctl (n =44) and ES-Tr (n =45). The ES-Ctl group 
received IM MeB12 and SC lidocaine injections, while the ES-Tr group received a combination 
SC injection of MeB12 and lidocaine, into the subcutaneous regions of the crusted lesions where 
the patients experienced pain. Frequency of dosing was once daily, 6 times per week for 2 
weeks. The patients were observed for the following hour and discharged without symptoms of 
discomfort. The patients’ NRS pain score was measured at baseline and each day of treatment.3 
For the purpose of this review, only baseline and day 14 were observed, assessing for 
improvement to a pain score < 3. 
Due to lack of improvement after receiving treatment for 8 days, one patient in the ES-Ctl 
group did not complete the study. One other participant of this group was lost to follow up after 
receiving 10 days of treatment. In the ES-Tr group, one subject dropped out because of a leg 
fracture. A total of 3 out of 89 participants (2 of group ES-Ctl and 1 of group ES-Tr) dropped out 
of this study.3  
At baseline, the control and intervention groups had similar mean pain scores. Group ES-
Tr had a mean pain score of 8.4, while group ES-Ctl had a mean pain score of 8.3. After a 
treatment period of 14 days, 96% of group ES-Tr reported an improved pain score < 3. In 
contrast, 13% of group ES-Ctl reported a pain score < 3.3 By calculating the NNT to be 2 
patients along with a CI of 1.06-1.43, these results are significant. It can be concluded that the 
combination SC injection with MeB12 provides a significant reduction in HZ neuropathic pain, 
in contrast to the use of IM MeB12 with SC Lidocaine that showed little benefit to the patients. 
Table 4: Pain NRS score at baseline and endpoint of intervention and control group, Xu3 
Xu3 Mean pain NRS at 
Baseline 
% of Pts with pain NRS < 3 
at 14-Day Endpoint 
RBI ABI NNT 
ES-Tr Intervention:  
SC Combo B12 + Lido 
8.4 (SD 1.5) 0.96 6.38 0.83 2 patients  
(CI  
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ES-Ctl Control:  
IM B12 + SC Lido 
8.3 (SD 1.2) 0.13 1.06-1.43) 
 
Safety and Tolerability 
The injections were well tolerated overall across all studies. There were no serious 
injuries or adverse events noted during the interventions or during the follow up periods.1,2,3 
DISCUSSION 
 The results from all studies suggest that treatment for HZ neuropathic pain could be 
improved by using SC MeB12 injections.  Xu1 showed significant improvement with SC MeB12 
as opposed to SC Lidocaine. Similarly, Xu2 and Xu3 showed significant improvement with SC 
combination of MeB12 and Lidocaine as opposed to IM MeB12 and SC Lidocaine. 
 Due to the increase in pain severity that is corelated with the increased age of patients, it 
is understandable for Xu2 and Xu3 to use only participants older than 50 years of age. With Xu1 
observing patients as young as 25 years old, incorporation of this study’s results into this review 
could provide a stronger idea of the effect MeB12 has on all ages.  
 If the treatment regimens used in these three studies were to be implemented in routine 
HZ treatment, patients would be required to receive injections 6 days per week for several 
weeks. This could pose an obstacle if patients have difficulty acquiring insurance. A more 
affordable solution could be to administer treatment during nurse visits. Depending on 
medication regulations, the patients can also be taught how to administer the injections at home 
to save them time and money on daily visits to the office.  
 Methylcobalamin is a common supplement, vitamin B12, taken over the counter. 
Although the recommended daily dose for adults is 2.4 micrograms, the body will only use what 
it needs, allowing the kidneys to excrete any excess. In the rare cases of patients with vitamin B12 
deficiencies, high doses of the supplement can cause dizziness, headaches, anxiety, nausea, or 
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vomiting. The most common cause of deficiency is from vegetarian diets. Possible interactions 
with other medications causes decreased absorption of the supplement.9 
Limitations  
Limitations to the studies used involve the participants. Although the amounts of patients 
that dropped out were small, they still had a significant effect in combination with the small 
sample size of participants. A larger number of patients would need to be used in future studies 
to make up for the dropout rates as well as to confirm the findings of these three studies. The 
authors believed that a limitation in their studies was in the treatment administration. The 
difficulty in blinding the local treatment injections could have had a negative effect on the 
results.1,2 Additional treatment limitations involve the dosing of the medications. Xu et al1 states 
that the dosing recommendations were based off of limited data. More studies need to be 
conducted to find the optimal dosing for treating PHN. Restrictions were also found in 
quantifying the pain by participants. The NRS pain scale can be subjective and difficult to 
regulate. Xu2 states that there was concern with patients reporting their pain scores over the 
phone. The authors believed that pain perception may be different or even more accurate during 
routine monitoring visits.  
CONCLUSION 
The evidence presented in this review is conclusive that including SC injections of 
MeB12 in the treatment regimen of HZ related neuropathic pain is clinically more effective than 
SC lidocaine injections alone. In future studies, it would be beneficial to extend the follow up 
period to ensure the efficacy of treating with SC MeB12 and confirm the lack of side effects. In 
order to improve pain scores even further, it may be advantageous to experiment with nerve 
block techniques with lidocaine and MeB12, rather than only subcutaneous injections, to involve 
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the full nerve track affected. Clinical use of MeB12 therapy has already shown to improve 
symptoms of peripheral neuropathy and autonomic dysfunction.1 The results of this review have 
now supported that local injections of MeB12 allows direct contact with the virus-damaged 
tissue to provide a neurological improvement. With continued studies to support these results, 
HZ patients in the future will benefit immensely. 
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